PetCaseFinder

Peer-reviewed veterinary case report

Heart fatty acid-binding protein is not a reliable marker for heart

By Casamián-Sorrosal, Domingo et al.·Published in The Veterinary record·2023·Veterinary Teaching Hospital & Department of Animal Medicine and Surgery, Spain·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Evaluation of heart fatty acid-binding protein as a biomarker for canine leishmaniosis.

Species:
dog

Plain-English summary

A group of dogs with leishmaniosis, a disease that can affect the heart, were tested for a specific protein (HFABP) that might indicate heart damage. Researchers found that the levels of this protein were not significantly different between sick dogs and healthy ones, and it didn't reliably show how severe the disease was. In fact, most dogs with leishmaniosis had HFABP levels similar to healthy dogs. This suggests that HFABP is not a useful marker for assessing heart issues in dogs with leishmaniosis.

People also search for: dog leishmaniosis symptoms · heart problems in dogs · canine leishmaniosis treatment options

Abstract

BACKGROUND: Myocarditis frequently occurs in canine leishmaniosis (CanL). Heart fatty acid-binding protein (HFABP) is a biomarker of myocardial damage. METHODS: This study aimed to compare HFABP concentration (HFABPc) in healthy dogs and dogs at different stages of CanL and evaluate the correlation of this biomarker with several clinicopathological and echocardiographic variables. Thirty-one dogs diagnosed with CanL and 10 healthy dogs were included. RESULTS: HFABPc was not statistically different (p > 0.05) between groups of dogs at different LeishVet stages of CanL or between groups with high versus low to intermediate serology titres. In 70% of CanL dogs, HFABPc was within the 95% confidence interval limits of the mean of healthy dogs. A moderate negative correlation with globulin (r = -0.519; p = 0.03) and haematocrit (HCT) (r = -0.538; p = 0.02) was observed. No other significant correlation (p > 0.05) was observed with any other variable. LIMITATIONS: Many statistical tests were performed, and therefore, type I error cannot be ruled out. CONCLUSION: HFABPc is not consistently elevated in dogs with CanL and is not associated with the severity of the disease, or most echocardiographic or clinicopathological variables studied. The correlation with globulin and HCT was not strong and not considered clinically significant. HFABPc lacks sufficient predictive capacity in dogs with CanL, discouraging further research or clinical use of this biomarker in this disease.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36755402/